Wegovy Tablets UK

Everything you need to know about oral semaglutide tablets, availability, dosing, clinical evidence and switching from injections.

For many people, GLP-1 medicines have changed the way they approach weight management, appetite control and long-term health. Until now, treatments such as Wegovy and Mounjaro have primarily been available as injections. Wegovy tablets introduce a new option: semaglutide-based weight management support in tablet form.

The main clinical study behind Wegovy tablets is called the OASIS 4 trial.

This was a Phase 3 clinical trial, which means it was a large study designed to test how well the treatment works and how safe it is before wider use.

The study included adults living with obesity, or adults who were overweight and had at least one weight-related health condition. People in the study received either oral semaglutide 25 mg once daily or a placebo, alongside diet and exercise support.

In the OASIS 4 trial, people taking oral semaglutide 25 mg lost significantly more weight than people taking placebo.

After 64 weeks, average weight loss was around 14–17%, depending on how the results were analysed.
Around one in three people who stayed on treatment lost 20% or more of their body weight.

The results from the oral tablet study were reported to be broadly comparable with the weekly injectable form of semaglutide used for weight management.

This may appeal to people who are new to GLP-1 treatment, nervous about injections, struggling with injection pens or simply looking for a clinically supported treatment option that fits more easily into their daily routine.

At Pharmulous, treatment is never supplied automatically. Every request is reviewed by a qualified prescriber who considers your medical history, current medications, treatment goals and overall suitability before making a prescribing decision.

Start your clinical assessment today to find out whether Wegovy tablets may be suitable for you.

Wegovy Tablets: Key Facts

Wegovy tablets contain semaglutide, a GLP-1 receptor agonist used for weight management.
Treatment is taken once daily alongside diet and lifestyle changes.

The UK approval of Wegovy tablets is based primarily on the OASIS 4 phase 3 clinical trial.
Participants in OASIS 4 achieved average weight loss of approximately 14% over 64 weeks.
Around one-third of participants achieved 20% or greater weight loss.

Wegovy tablets may provide an alternative option for suitable patients who prefer tablets to injections.

Treatment suitability should always be assessed by a qualified healthcare professional.

For further information, visit our Wegovy Tablets page.

Switching from Wegovy Injections to Wegovy Tablets

Some patients may wish to switch from Wegovy injections to Wegovy tablets once available.

Potential reasons for considering a switch include:

• Preference for oral treatment.
• Difficulty with injections.
• Convenience when travelling.
• Long-term treatment preferences.

Any switch should be reviewed by a healthcare professional, who can assess suitability and advise on the most appropriate dosing strategy.

Patients should not switch treatments without professional medical advice.

What Are Wegovy Tablets?

Wegovy tablets contain semaglutide, a GLP-1 receptor agonist used to support weight management in suitable adults.

GLP-1 medicines mimic a naturally occurring hormone involved in appetite regulation, feelings of fullness, digestion and blood sugar control.

When used alongside a reduced-calorie diet and increased physical activity, semaglutide may help suitable patients:

• Feel fuller for longer
• Reduce hunger
• Help manage food cravings
• Support portion control
• Support weight management goals
• Encourage long-term healthy lifestyle changes

Unlike Wegovy injections, Wegovy tablets are taken orally as part of a daily routine.

For patients interested in GLP-1 treatment but hesitant about injections, oral semaglutide may provide a more familiar and accessible option.

Wegovy Tablet Strengths Available in the UK

Wegovy tablets are available in four strengths in the UK:

• 1.5mg tablets
• 4mg tablets
• 9mg tablets
• 25mg tablets

Treatment usually begins at the lowest dose and increases gradually over several months. This process is known as dose escalation or titration.

Gradually increasing the dose allows the body to adapt to treatment and may help reduce common gastrointestinal side effects such as nausea, vomiting, diarrhoea and stomach discomfort.

Your Pharmulous prescriber will determine the most appropriate dosing schedule based on your clinical assessment, treatment response and tolerability.

Once-daily oral semaglutide for weight management in eligible adults, alongside diet and lifestyle support.

This schedule may vary depending on how well treatment is tolerated.

Some patients may remain on a lower dose for longer if side effects occur, while others may progress according to the standard escalation schedule.

Dose adjustments should only be made under the supervision of a qualified prescriber.

Why Choose Wegovy Tablets?

Wegovy tablets may be suitable for patients who want GLP-1 support without injections.

They may be particularly appealing for people who:

• Are new to GLP-1 treatment
• Prefer tablets to injections
• Feel anxious about needles
• Want semaglutide treatment in oral form
• Find injection pens difficult to usePrefer a discreet daily treatment option
• Want support through a doctor-led weight management service
• Are looking for long-term weight management support
• Meet clinical suitability criteria

A tablet-based treatment is not automatically better than an injection. Some patients prefer the convenience of a once-weekly injection, while others prefer taking a daily tablet.

The most appropriate option depends on your medical history, lifestyle, treatment goals and clinical suitability.

A Strong Option for Patients New to GLP-1 Treatment

Starting weight loss medication can feel like a significant step.

For many people, concerns about injections are one of the biggest barriers to beginning treatment. Wegovy tablets may help overcome this concern by offering semaglutide in a tablet format rather than an injectable pen.

This can make treatment feel more approachable, particularly for people who have never used a GLP-1 medicine before.

However, starting any prescription weight loss treatment requires appropriate clinical support. Dosing instructions, potential side effects, medical history and long-term treatment planning all play an important role.

That is why Wegovy tablets should only be accessed through a regulated prescribing service with appropriate clinical oversight.

The OASIS 4 Clinical Trial

The UK approval of Wegovy tablets is based primarily on the OASIS 4 phase 3 clinical trial, which evaluated once-daily oral semaglutide 25 mg in adults living with obesity or overweight.

The study followed participants for 64 weeks alongside dietary and lifestyle interventions.

Key findings included:

• Average weight loss of approximately 14%.
• Weight loss of approximately 16.6% among participants who remained on treatment as intended.
• Around one-third of participants achieved 20% or greater weight loss.
• Improvements in waist circumference and other cardiometabolic health markers.

These results demonstrate that oral semaglutide may offer a clinically meaningful weight management option for appropriately selected patients.

Could Wegovy Tablets Help With Weight Maintenance?

Weight maintenance is often one of the most challenging stages of a weight management journey.

Many people can achieve weight loss initially, but maintaining those results over time can be more difficult due to appetite changes, cravings and lifestyle factors.

For some suitable patients, Wegovy tablets may be considered as part of a longer-term weight management strategy.

This may include patients who have previously used injectable treatments such as Wegovy or Mounjaro and wish to discuss whether an oral treatment option could be appropriate.

Any change in treatment should only take place following clinical review and guidance.

Can I Switch From Mounjaro Injections to Wegovy Tablets?

Some patients currently using injectable weight loss medications may be interested in switching to a tablet-based option.

Wegovy tablets may be suitable for certain patients who would prefer a needle-free treatment, are finding injections difficult to continue, or are looking for an alternative option for long-term weight management.

However, switching from Mounjaro to Wegovy tablets is not a direct equivalent change.

Mounjaro contains tirzepatide, whereas Wegovy tablets contain semaglutide. These medicines work differently and should not be used together.

Before recommending a switch, Pharmulous prescribers will review:

• Current medication and dosage
• Treatment response
• Side effects experienced
• Weight management progress
• Medical history
• Timing of previous injections

For some patients, remaining on their current treatment may be the most appropriate option. For others, Wegovy tablets may offer a suitable alternative.

Wegovy Tablets vs Wegovy Injections

Both Wegovy tablets and Wegovy injections contain semaglutide but differ in how they are administered.

Wegovy Tablets

• Oral administration
• Needle-free option
• Taken once daily
• Requires specific timing and administration instructions

Wegovy Injections

• Taken once weekly
• Administered using an injection pen
• Less frequent dosing schedule
• May suit patients who prefer a weekly routine

A prescriber will consider several factors before recommending treatment, including:

• BMI
• Weight-related medical conditions
• Current medications
• Previous weight loss treatments
• Side effect history
• Pancreatic, gallbladder, stomach or thyroid conditions
• Pregnancy or fertility plans
• Ability to follow tablet dosing instructions
• Long-term treatment goals

The safest treatment option is always the one that is clinically appropriate for your circumstances.

How Do You Take Wegovy Tablets?

Wegovy tablets must be taken correctly to ensure optimal absorption.

They are typically taken:

• Once daily
• First thing in the morning
• On an empty stomach
• With a small amount of water only
• At least 30 minutes before eating, drinking or taking other oral medicines

Following these instructions is important because incorrect administration may affect how well the medicine is absorbed and how effectively treatment works.

If treatment is approved, your Pharmulous prescriber will provide detailed guidance on dosing, administration, side effects and ongoing support.

What Are the Possible Side Effects of Wegovy Tablets?

Like all prescription medicines, Wegovy tablets can cause side effects.

Common side effects associated with semaglutide may include:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Stomach discomfort
• Indigestion
• Reduced appetite

Many side effects are temporary and may improve as your body adjusts to treatment.

Patients should always read the patient information leaflet and seek medical advice if they experience severe or concerning symptoms.

Who Is Eligible for Wegovy Tablets?

Wegovy tablets are prescription-only medicines and are not suitable for everyone.

Treatment suitability depends on a full clinical assessment and may take into account:

• BMI
• Weight-related health conditions
• Current medications
• Previous weight management treatments
• Medical history
• Pregnancy or fertility plans

Wegovy tablets may not be suitable for individuals who:

• Are pregnant or breastfeeding
• Are trying to conceive
• Are already taking another GLP-1 medication
• Have certain pancreatic, gallbladder, stomach or thyroid-related conditions
• Have previously experienced significant GLP-1 side effects
• Cannot follow the required dosing instructions

If treatment is not appropriate, our clinical team will explain why and discuss alternative options where suitable.

Why Choose Pharmulous for Wegovy Tablets?

At Pharmulous, we are a doctor-led online pharmacy and weight management service.

Every consultation includes:

• Doctor-led clinical review
• Comprehensive suitability assessment
• BMI and weight-related health evaluation
• Medication and medical history screening
• Safety-focused prescribing decisions
• Clear dosing instructions
• Side effect guidance
• Ongoing treatment support
• Support with treatment changes and maintenance planning

Weight management is not one-size-fits-all. Every patient deserves personalised clinical care based on their individual circumstances and goals.

Clinical Evidence Summary

Wegovy tablets contain semaglutide, a GLP-1 receptor agonist that has been extensively studied for weight management in adults living with obesity or overweight.

The UK approval of Wegovy tablets is based primarily on the OASIS 4 phase 3 clinical trial, which evaluated once-daily oral semaglutide 25 mg alongside dietary and lifestyle interventions.

In OASIS 4, participants achieved average weight loss of approximately 14% over 64 weeks when analysed regardless of treatment adherence. Among participants who remained on treatment as intended, average weight loss reached approximately 16.6%.

Around one-third of participants achieved 20% or greater weight loss. Improvements were also observed in waist circumference and other cardiometabolic health markers.

Wegovy tablets should be used alongside a reduced-calorie diet, increased physical activity and ongoing clinical support. Treatment suitability should always be assessed by a qualified healthcare professional.

Frequently Asked Questions

Are Wegovy tablets available in the UK?

Wegovy tablets were approved by MHRA on 11 June 2026 and will be available for eligible patients in the UK, subject to clinical assessment, prescriber approval and stock availability.

What strengths do Wegovy tablets come in?

Wegovy tablets are available in 1.5mg, 4mg, 9mg and 25mg strengths.

What is the maintenance dose of Wegovy tablets?

For many patients, the maintenance dose is 25mg once daily following successful dose escalation and prescriber review.

I'm currently taking Wegovy 2.4 mg injections. Can I switch to tablets?

Wegovy 25 mg tablets are generally considered the equivalent maintenance treatment option to Wegovy 2.4 mg weekly injections. Although the tablet dose appears much higher, oral semaglutide is absorbed differently by the body, meaning a larger tablet dose is required to achieve comparable levels of the active ingredient in the bloodstream. As a result, Wegovy 25 mg tablets and Wegovy 2.4 mg injections are intended to provide similar therapeutic exposure when taken as prescribed.

Any switch between injectable and oral treatment should be made under the guidance of a qualified healthcare professional, who will advise on the most appropriate treatment plan for your individual circumstances.

Can I switch from Mounjaro to Wegovy tablets?

Some patients may be able to switch following a clinical review. Your prescriber will determine whether switching is safe and appropriate.

Are Wegovy tablets suitable for everyone?

No. Suitability depends on individual medical circumstances and requires assessment by a qualified prescriber.

How can I buy Wegovy tablets?

The first step is completing a Pharmulous clinical assessment. A qualified prescriber will review your information and determine whether treatment is appropriate.

Start Your Wegovy Tablet Assessment Today

Wegovy tablets offer a new needle-free option for eligible patients seeking clinically supervised weight management support.

Whether you are new to GLP-1 treatment, prefer tablets to injections, or are exploring options for long-term weight management, our doctor-led team can help determine whether Wegovy tablets are appropriate for you.

Complete your Pharmulous clinical assessment today and receive a personalised review from our qualified prescribing team.

References

• Wharton S, et al. Oral Semaglutide 25 mg for Weight Management in Adults with Obesity or Overweight: OASIS 4 Phase 3 Clinical Trial. Presented at ObesityWeek 2024.
• O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and Safety of Oral Semaglutide 50 mg Once Daily in Adults with Overweight or Obesity (OASIS 1). The Lancet. 2023;402(10403):705-719.
• Novo Nordisk. OASIS Clinical Development Programme for Oral Semaglutide in Weight Management.
• Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity. JAMA. 2021;325(14):1414-1425.
• National Institute for Health and Care Excellence (NICE). Semaglutide for Managing Overweight and Obesity. Available at: https://www.nice.org.uk
• Medicines and Healthcare products Regulatory Agency (MHRA). Regulatory Information and Prescribing Guidance for Semaglutide Products. Available at: https://www.gov.uk/mhra